- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01200173
Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers
November 23, 2016 updated by: Danone Research
This multicentric, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel® = tested product) on the incidence of respiratory and gastro-intestinal common infectious diseases (cumulated number of infections during the intervention period: primary criteria) in children aged 3-6 years, attending day care centers.Volunteers received either 200g/day of tested product (N=300) or control product (N=299) for 3-months, followed by a 1-month follow-up.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
600
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation, 117997
- Federal State Institution "Federal research center of pediatric hematology, oncology and imunology"
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 6 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject whose parents/legal guardians had given written informed consent,
- Male or female, aged 3 to 6 years (upper bound excluded),
- Attending day-care centres or preschools 5 days a week in the Moscow area,
- Subject found medically healthy (in particular, free of respiratory and GI tract symptoms),
- Subject who appreciated dairy products and multi-fruit flavour.
Exclusion Criteria:
- Subject whose parents were not reading and writing Russian, or not understanding informed consent or study protocol.
- Subject with allergy or hypersensitivity to milk proteins or dairy foods components (ex: lactose, milk proteins), or with any known food or respiratory allergy.
- Subject presenting a severe evolutive or chronic pathology (Ex: cancer, tuberculosis, Crohn disease, cirrhosis, multiple sclerosis, Type I diabetes…) or any past or actual health condition that could interfere with the outcome of the study (Ex: HIV, Chemotherapy, malabsorption, ulcer, celiac disease, failure to thrive…).
- Subject having experienced any infectious disease during the last 7 days.
- Subject with current diarrhoea or constipation Subject who was frequently using laxatives or who had been using laxatives during the week prior his participation to the study.
- Subject who was under artificial nutrition, had gastro-intestinal surgery or any intervention requiring general anaesthesia the last 2 months prior to his participation to the study.
- Subject with special medicated diet (obesity, anorexia, metabolic pathology, nutritional complementation…) or with eating disorders (anorexia, bulimia…).
- Subject currently receiving, or who had received during the last months, systemic treatment or topical treatment likely to interfere with evaluation of the study parameters: antibiotics, antiseptics, antifungal, corticoids, vaccines, anti-histaminic molecules, non-corticoid antiinflammatory substances, immunosuppressant treatment…
- Subject already enrolled in another clinical study, or currently under an exemption period from a previous study.
- Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1 = Tested product
|
|
Sham Comparator: 2 = Control product
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
April 1, 2007
Study Completion (Actual)
July 1, 2007
Study Registration Dates
First Submitted
September 10, 2010
First Submitted That Met QC Criteria
September 10, 2010
First Posted (Estimate)
September 13, 2010
Study Record Updates
Last Update Posted (Estimate)
November 25, 2016
Last Update Submitted That Met QC Criteria
November 23, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NU206
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Infectious Diseases
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.CompletedCommon WartUnited States
-
Aclaris Therapeutics, Inc.Completed
-
Assiut UniversityUnknown
-
Aclaris Therapeutics, Inc.Completed
-
Karo Pharma ABCompletedPlantar Wart | Common WartPoland
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
G&E Herbal Biotechnology Co., LTDSuspended
Clinical Trials on 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)
-
Danone ResearchTerminatedGastroenteritis | Sinusitis | Otitis | Bronchitis | Upper Respiratory Tract Infections | Sore Throat | Flu | Lower Respiratory Tract Infections | Rhinopharyngitis | Pneumopathy | Flu-like SyndromesFrance
-
Danone ResearchCompletedRespiratory Tract Infections | Pneumonia | Gastroenteritis | Sinusitis | Influenza | Healthy Subjects | Otitis | Infectious Diseases | Bronchitis | Sore ThroatGermany